Solid Biosciences Inc..
SLDB.US | Research and experimental development on natural sciences and engineering
Solid Biosciences Inc. is a biotechnology company focused on developing disease-modifying therapies for Duchenne muscular dystrophy (DMD). The company's lead product candidate is SGT-001, an adeno-associated virus (AAV) mediated gene therapy designed to address the underlying genetic cause of DMD by...Show More
Better Health for All
40
Solid Biosciences Inc. is entirely focused on developing disease-modifying gene therapies for severe conditions like Duchenne muscular dystrophy (DMD) and Catecholaminergic polymorphic ventricular tachycardia (CPVT).
1
Its lead product candidate, SGT-001, and next-generation therapy, SGT-003, aim to deliver substantial health benefits, with SGT-003 showing positive initial data including significant microdystrophin expression and reduced muscle injury markers in DMD patients.
2
The company has no product revenue and no revenue from products with established negative health outcomes.
3
For its SGT-001 gene therapy, there have been three serious safety issues leading to FDA clinical holds due to serious kidney and blood-related injuries in a patient.
4
In contrast, the newer SGT-003 therapy has been well-tolerated in the first six participants, with no serious adverse events observed as of February 2025.
5
The company's research and development expenses were $76.6 million in 2023, representing 100% of its operating expenses, demonstrating a complete allocation to health innovation.
6
The company emphasizes patient safety and well-being in its clinical trial design and execution.
7
Fair Money & Economic Opportunity
0
Solid Biosciences Inc. is a biotechnology company focused on developing therapies for rare diseases, not a financial institution.
1
The company's core business does not involve lending, deposit services, or other financial products for consumers.
2
Therefore, all KPIs related to financial services, pricing, fees, lending practices, customer financial outcomes, and data portability are not applicable to its operations.
Fair Pay & Worker Respect
0
No specific, quantitative evidence was found in the provided articles for any of the KPIs under the 'Fair Pay & Worker Respect' value. While articles mention a comprehensive benefits program, competitive compensation, and a Code of Business Conduct and Ethics
1
, they do not provide concrete data points such as living wage coverage, CEO to median pay ratio, collective bargaining share, safety incident rates, pay equity ratios, worker engagement scores, turnover rates, labor violation incidents, insecure contract share, or health insurance coverage percentages for the general workforce. Workforce reductions of 35% in April 2022 and 18% in December 2022 were noted, but these are company-initiated reductions, not voluntary turnover.
2
Glassdoor ratings for compensation and benefits (4.7/5) and diversity and inclusion (4.5/5) are qualitative assessments and not direct quantitative metrics for the KPIs.
3
Fair Trade & Ethical Sourcing
0
No evidence available to assess Solid Biosciences Inc. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
-30
The company's Form 10-K filing for the period ending December 31, 2023, indicates that its financial statements do not reflect the correction of an error to previously issued financial statements, nor were there any error corrections that required a recovery analysis of incentive-based compensation.
1
The company is subject to anti-corruption laws, including the U.K. Bribery Act 2010 and the U.S. Foreign Corrupt Practices Act (FCPA), which prohibit bribery and prohibited payments.
2
The company performs extensive audits of contract laboratories, manufacturers, and suppliers to ensure compliance with cGMP requirements.
3
Kind to Animals
0
No evidence available to assess Solid Biosciences Inc. on Kind to Animals.
No War, No Weapons
0
Solid Biosciences Inc. is a biotechnology company focused on developing gene therapies for neuromuscular and cardiac diseases.
1
The provided articles consistently describe the company's R&D and operations as solely within this medical field. There is no evidence of the company developing or selling any dual-use products or technologies with potential military applications, nor is there any indication of involvement in defense-related business activities. Therefore, the KPIs related to dual-use technology and board oversight of defense business are scored as N/A.
Planet-Friendly Business
0
No evidence available to assess Solid Biosciences Inc. on Planet-Friendly Business.
Respect for Cultures & Communities
0
No data related to Solid Biosciences Inc.'s respect for cultures or communities, or any specific metrics outlined in the rubric, was found in the provided article.
1
The article focuses on the company's gene therapy pipeline for neuromuscular and cardiac diseases.
2
Safe & Smart Tech
0
No evidence available to assess Solid Biosciences Inc. on Safe & Smart Tech.
Zero Waste & Sustainable Products
0
No evidence available to assess Solid Biosciences Inc. on Zero Waste & Sustainable Products.